Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 13,740 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Reduction of Unwanted Fat
Interventions: Zeltiq Dermal Cooling Device; Device
Lead sponsor: Zeltiq Aesthetics; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 8 more

Conditions: Trauma, Opioid Use, Spine Fusion
Interventions: Oxycodone, Ketorolac, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hemophilia A
Interventions: New FVIII products; Drug
Lead sponsor: Bayer; Industry
Eligibility: 2 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 27
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 23 more

Conditions: Relapsed/Refractory Acute Lymphoblastic Leukemia
Interventions: Other; Other
Lead sponsor: Amgen; Industry
Eligibility: Not listed
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 14 more

Conditions: Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Interventions: Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 872
States / cities: Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more

Conditions: Pertussis, Tetanus, Diphtheria
Interventions: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 647 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more

Conditions: Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Solid Tumors With PIK3Ca Mutation
Interventions: TPST-1495 twice daily, TPST-1495 once daily or on intermittent schedule, Pembrolizumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Baltimore, Maryland • Springfield, Massachusetts + 8 more

Conditions: Acute Pancreatitis
Interventions: Dexcom Continuous Glucose Monitor (CGM); Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more

Conditions: Pressure Ulcer
Interventions: Envision® Patient Support System; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K, Food Effect of ASP015K
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Neoplasms, Cancer of the Breast, Breast Cancer
Interventions: Gemcitabine, Trastuzumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 13
States / cities: Hot Springs, Arkansas • Pine Bluff, Arkansas • Redding, California + 10 more

Conditions: Drug-Interactions
Interventions: Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
Interventions: Bevacizumab, Docetaxel, Filgrastim, Gemcitabine Hydrochloride, Pegfilgrastim, Placebo; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 201
States / cities: Phoenix, Arizona • Burbank, California • Concord, California + 138 more

Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Interventions: Non-Interventional, Non-Interventional Follow-up; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more

Conditions: Ovarian Neoplasms
Interventions: Olaratumab, liposomal doxorubicin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 6
States / cities: Joliet, Illinois • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: Trichiasis
Interventions: azithromycin, topical tetracycline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Peanut Allergy
Interventions: Viaskin Peanut 250µg; Drug
Lead sponsor: DBV Technologies; Industry
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more

Conditions: Ovarian Cancer, Endometrial Cancer
Interventions: everolimus and letrozole; Drug
Lead sponsor: Sinai Hospital of Baltimore; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Meningioma
Interventions: hydroxyurea; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2011
U.S. locations: 133
States / cities: Fairbanks, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 97 more

Conditions: HIV Infection
Interventions: GW873140; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 34
States / cities: Tucson, Arizona • Laguna Beach, California • Long Beach, California + 30 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 955
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more

Conditions: Leukemia, Lymphoma
Interventions: Filgrastim, Rituximab, Cyclophosphamide, Cytarabine, Methotrexate, Prednisone, Hydrocortisone, Vincristine, Leucovorin; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 30 Years to 120 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: APF530, dexamethasone, Palonosetron Hydrochloride, placebo; Drug · Other
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 1,428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 52
States / cities: Anniston, Alabama • Glendale, Arizona • Tucson, Arizona + 46 more

Conditions: Asthma
Interventions: Pediatric Asthma Alert (PAAL), Standard asthma education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 10 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Non-Invasive Cooling of Fat Cells

Relieving Acute Pain (RAP) Study: A Pilot Study

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

Envision® Surface Evaluation

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer

Study of Azithromycin to Prevent Recurrent Trichiasis Following Surgery in Ethiopia

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia

APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Pediatric Asthma Alert Intervention for Minority Children With Asthma